| Disease | 86 PATIENTS WITH LUNG CANCER WERE ENROLLED IN THIS PHASE II STUDY. LUNG CANCERS TREATED INCLUDE SMALL CELL CARCINOMA, ADENOCARCINOMA, SQUAMOUS CARCINOMA AND LARGE CELL CARCINOMA. DRUG INFUSIONS WERE GIVEN FOR 5 CONSECUTIVE DAYS AT 21 DAY INTERVALS
AMONG 80 EVALUABLE PATIENTS, THERE WERE 3 PARTIAL RESPONSES. 2 OF THESE WERE IN PATIENTS WITH ADENOCARCINOMA, AND 1 WAS IN A PATIENT WITH SQUAMOUS CARCINOMA. THE OVERALL MEDIAN SURVIVAL TIME WAS 17 WEEKS.
NEUROTOXIC EFFECTS WERE DOSE LIMITING AND INCLUDED TRANSIENT LETHARGY, SOMNOLENCE, COMA, CONFUSION, HALLUCINATION, MILD HYPERACTIVITY, TREMOR, CONVULSIONS, AND STATUS EPILEPTICUS. HEMATOLOGIC TOXICITY WAS ALSO EVIDENT. |